CN111575348B - 宏基因组文库及建库方法和应用 - Google Patents
宏基因组文库及建库方法和应用 Download PDFInfo
- Publication number
- CN111575348B CN111575348B CN202010425415.9A CN202010425415A CN111575348B CN 111575348 B CN111575348 B CN 111575348B CN 202010425415 A CN202010425415 A CN 202010425415A CN 111575348 B CN111575348 B CN 111575348B
- Authority
- CN
- China
- Prior art keywords
- library
- nucleic acid
- fragmentation
- buffer
- transposase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 54
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 52
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 52
- 108010020764 Transposases Proteins 0.000 claims abstract description 36
- 102000008579 Transposases Human genes 0.000 claims abstract description 36
- 238000013467 fragmentation Methods 0.000 claims abstract description 34
- 238000006062 fragmentation reaction Methods 0.000 claims abstract description 34
- 230000003321 amplification Effects 0.000 claims abstract description 32
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 32
- 238000010276 construction Methods 0.000 claims abstract description 29
- 239000000872 buffer Substances 0.000 claims abstract description 26
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 244000052769 pathogen Species 0.000 claims abstract description 23
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 238000007259 addition reaction Methods 0.000 claims abstract description 3
- 239000012467 final product Substances 0.000 claims abstract description 3
- 239000012634 fragment Substances 0.000 claims description 56
- 239000011324 bead Substances 0.000 claims description 24
- 239000007853 buffer solution Substances 0.000 claims description 15
- 238000012163 sequencing technique Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 12
- 229920006176 crosslinked polyethyleneglycol Polymers 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229920003080 Povidone K 25 Polymers 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000002835 absorbance Methods 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010048612 Hydrothorax Diseases 0.000 claims description 3
- 108010012306 Tn5 transposase Proteins 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 238000003766 bioinformatics method Methods 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 238000005457 optimization Methods 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 15
- 238000010586 diagram Methods 0.000 description 12
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 241000193985 Streptococcus agalactiae Species 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- -1 cerebrospinal fluid Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000007440 host cell apoptosis Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
试剂/纯度 | 总量 | |
核酸 | OD260/OD280=1.98 | 1.2ng |
转座酶复合体(诺唯赞,S111) | / | 0.17μg |
PVP/PEG | 分析纯 | 6%体积占比 |
5×Tagment Buffer(诺唯赞,S111) | / | 4μL |
试剂/纯度 | 总量或浓度 | |
Hifi taq酶 | / | 1U |
5×PCR扩增buffer | / | 10μL |
扩增引物 | PAGE | 10pmol/L |
温度 | 时间 | 循环 |
25℃ | 15min | / |
65℃ | 15min | / |
温度 | 时间 | 循环 |
20℃ | 15min | / |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010425415.9A CN111575348B (zh) | 2020-05-19 | 2020-05-19 | 宏基因组文库及建库方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010425415.9A CN111575348B (zh) | 2020-05-19 | 2020-05-19 | 宏基因组文库及建库方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111575348A CN111575348A (zh) | 2020-08-25 |
CN111575348B true CN111575348B (zh) | 2024-01-09 |
Family
ID=72117257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010425415.9A Active CN111575348B (zh) | 2020-05-19 | 2020-05-19 | 宏基因组文库及建库方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111575348B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112646859B (zh) * | 2020-12-30 | 2022-04-26 | 中国人民解放军疾病预防控制中心 | 一种基于宏基因组学的呼吸道咽拭子样本的建库方法和病原检测方法 |
CN113658635B (zh) * | 2021-08-24 | 2023-09-29 | 北京诺禾致源科技股份有限公司 | 核酸检测结果的自动判定方法、装置及其应用 |
CN114350749A (zh) * | 2022-01-04 | 2022-04-15 | 长沙金域医学检验实验室有限公司 | 一种基于宏基因组测序的游离核酸建库方法 |
CN114395614A (zh) * | 2022-02-23 | 2022-04-26 | 辽宁康惠生物科技有限公司 | 一种高通量快速检测体液宏基因组病原微生物的方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106795651A (zh) * | 2014-06-26 | 2017-05-31 | 伊鲁米那股份有限公司 | 利用单管添加方案的加标签的核酸的文库制备 |
CN106995836A (zh) * | 2016-01-22 | 2017-08-01 | 益善生物技术股份有限公司 | 二代测序样品前处理的引物和方法以及试剂盒 |
CN107523640A (zh) * | 2017-10-12 | 2017-12-29 | 厦门燕旭安生物科技有限公司 | 一种ctDNA精准测序的扩增子文库构建方法 |
CN107557450A (zh) * | 2017-10-09 | 2018-01-09 | 湖南大地同年生物科技有限公司 | 一种快速构建高通量测序文库的试剂及方法及其应用 |
CN107586835A (zh) * | 2017-10-19 | 2018-01-16 | 东南大学 | 一种基于单链接头的下一代测序文库的构建方法及其应用 |
CN108048450A (zh) * | 2017-12-21 | 2018-05-18 | 广州赛哲生物科技股份有限公司 | 一种痰液微生物宏基因组去宿主化提取和建库方法 |
CN109207572A (zh) * | 2018-09-29 | 2019-01-15 | 苏州贝康医疗器械有限公司 | 单细胞高通量测序文库构建方法及其试剂盒 |
CN110564705A (zh) * | 2019-09-30 | 2019-12-13 | 苏州璞瑞卓越生物科技有限公司 | 一种用于转座酶片段化的试剂及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017151828A1 (en) * | 2016-03-01 | 2017-09-08 | Universal Sequencing Technology Corporation | Methods and kits for tracking nucleic acid target origin for nucleic acid sequencing |
CN109996892B (zh) * | 2016-12-07 | 2023-08-29 | 深圳华大智造科技股份有限公司 | 单细胞测序文库的构建方法及其应用 |
-
2020
- 2020-05-19 CN CN202010425415.9A patent/CN111575348B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106795651A (zh) * | 2014-06-26 | 2017-05-31 | 伊鲁米那股份有限公司 | 利用单管添加方案的加标签的核酸的文库制备 |
CN106995836A (zh) * | 2016-01-22 | 2017-08-01 | 益善生物技术股份有限公司 | 二代测序样品前处理的引物和方法以及试剂盒 |
CN107557450A (zh) * | 2017-10-09 | 2018-01-09 | 湖南大地同年生物科技有限公司 | 一种快速构建高通量测序文库的试剂及方法及其应用 |
CN107523640A (zh) * | 2017-10-12 | 2017-12-29 | 厦门燕旭安生物科技有限公司 | 一种ctDNA精准测序的扩增子文库构建方法 |
CN107586835A (zh) * | 2017-10-19 | 2018-01-16 | 东南大学 | 一种基于单链接头的下一代测序文库的构建方法及其应用 |
CN108048450A (zh) * | 2017-12-21 | 2018-05-18 | 广州赛哲生物科技股份有限公司 | 一种痰液微生物宏基因组去宿主化提取和建库方法 |
CN109207572A (zh) * | 2018-09-29 | 2019-01-15 | 苏州贝康医疗器械有限公司 | 单细胞高通量测序文库构建方法及其试剂盒 |
CN110564705A (zh) * | 2019-09-30 | 2019-12-13 | 苏州璞瑞卓越生物科技有限公司 | 一种用于转座酶片段化的试剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111575348A (zh) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111575348B (zh) | 宏基因组文库及建库方法和应用 | |
CN109996892B (zh) | 单细胞测序文库的构建方法及其应用 | |
US9855559B2 (en) | Microorganism nucleic acid purification from host samples | |
AU2016386032B2 (en) | Deep sequencing profiling of tumors | |
CN111471676A (zh) | 一种宏基因组二代测序的建库样本的制备方法 | |
WO2017084023A1 (zh) | 一种高通量的单细胞转录组建库方法 | |
CN113061648B (zh) | 一种采用Tn5转座酶辅助构建微量样品m6A修饰检测文库的方法及其应用 | |
WO2021114713A1 (zh) | 细胞裂解液、试剂盒及应用 | |
US20190225958A1 (en) | Method for enrichment and purification of cell-free dna from body fluid for high-throughput processing | |
Han et al. | Saliva diagnosis using small extracellular vesicles and salivaomics | |
CN110945143A (zh) | 利用下一代测序方法的靶蛋白的聚类定量方法及其用途 | |
CN112646859B (zh) | 一种基于宏基因组学的呼吸道咽拭子样本的建库方法和病原检测方法 | |
Mathay et al. | Method validation for extraction of nucleic acids from peripheral whole blood | |
Fang et al. | Depletion of ribosomal RNA sequences from single‐cell RNA‐sequencing library | |
CN111926394B (zh) | 基于宏基因组学的建库方法和检测试剂盒 | |
CN110656168A (zh) | 一种copd早期诊断标志物及其应用 | |
Glenn et al. | Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis | |
Ruiz-Ojeda et al. | RNA Analyses | |
CN117070511B (zh) | 一种用于扩增人类线粒体全基因组的引物组及其应用 | |
Oomen et al. | SisterC: A novel 3C-technique to detect chromatin interactions between and along sister chromatids | |
GB2621159A (en) | Methods of preparing processed nucleic acid samples and detecting nucleic acids and devices therefor | |
Hamnevoll | Optimization of the use of PrepFiler Express™ Forensic DNA extraction kit lysis buffer discard for mRNA profiling | |
CN108474024B (zh) | 磁性玻璃颗粒对核酸的连续捕获 | |
Cortázar et al. | Genome-wide Mapping of 5′-monophosphorylated Ends of Mammalian Nascent RNA Transcripts | |
CN117844884A (zh) | 一种cfDNA末端修复及建库的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201013 Address after: 510130 No. 301, building G10, South China new material innovation park, self compiled building 3, No. 31, Kefeng Road, Guangzhou high tech Industrial Development Zone, Guangdong Province Applicant after: Guangzhou Weiyuan Medical Equipment Co.,Ltd. Applicant after: GUANGZHOU VISION GENE TECHNOLOGY Co.,Ltd. Applicant after: Guangzhou Weiyuan medical laboratory Co.,Ltd. Applicant after: Shenzhen Weiyuan Medical Technology Co.,Ltd. Applicant after: Weiyuan (Shenzhen) Medical Research Center Co.,Ltd. Address before: 510130 Three South China New Materials Innovation Park G10 Building 303, No. 31 Kefeng Road, Guangzhou High-tech Industrial Development Zone, Guangdong Province Applicant before: GUANGZHOU VISION GENE TECHNOLOGY Co.,Ltd. Applicant before: Guangzhou Weiyuan Medical Equipment Co.,Ltd. Applicant before: Guangzhou Weiyuan medical laboratory Co.,Ltd. Applicant before: Shenzhen Weiyuan Medical Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230901 Address after: Room 301, G10, South China new material innovation park, building 3, No. 31, Kefeng Road, Guangzhou hi tech Industrial Development Zone, Guangdong 510130 Applicant after: Guangzhou Weiyuan Medical Equipment Co.,Ltd. Applicant after: GUANGZHOU VISION GENE TECHNOLOGY Co.,Ltd. Applicant after: Guangzhou Weiyuan medical laboratory Co.,Ltd. Applicant after: Shenzhen Weiyuan Medical Technology Co.,Ltd. Address before: Room 301, G10, South China new material innovation park, building 3, No. 31, Kefeng Road, Guangzhou hi tech Industrial Development Zone, Guangdong 510130 Applicant before: Guangzhou Weiyuan Medical Equipment Co.,Ltd. Applicant before: GUANGZHOU VISION GENE TECHNOLOGY Co.,Ltd. Applicant before: Guangzhou Weiyuan medical laboratory Co.,Ltd. Applicant before: Shenzhen Weiyuan Medical Technology Co.,Ltd. Applicant before: Weiyuan (Shenzhen) Medical Research Center Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |